Clarithromycin: A Promising Immunomodulator in Sepsis
Severe sepsis and septic shock are among the leading causes of death, representing the 10th most common cause of death in the United States of America . The high mortality rates, ranging between 35 and 50 % despite adequate antimicrobial treatment , have encouraged intense research efforts to better understand the mechanisms underlying the pathogenesis of sepsis. As a consequence, sepsis syndrome is now recognized as a complex entity created by an intense inflammatory reaction that is generated in the host after stimulation of the innate and adaptive immune systems by bacterial components .
KeywordsCystic Fibrosis Septic Shock Severe Sepsis Antimicrob Agent Pneumococcal Pneumonia
Unable to display preview. Download preview PDF.
- 14.Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J (in press)Google Scholar
- 26.Giamarellos-Bourboulis EJ (2008) Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents (in press)Google Scholar